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Aim: The aim of this study was to determine and compare the effect of treatment with transdermal oestrogen and phytoestrogen on insulin
sensitivity and sex hormone-binding globulin (SHBG) levels in healthy postmenopausal women.
Methods: Forty-three healthy postmenopausal women aged 68 ± 7 (mean ± SD) years who were not receiving hormonal replacement
therapy completed a 3 month randomized drug therapy study. The participants were randomized to one of four groups: 0.05 mg or 0.1 mg
transdermal oestrogen/day, or 40 or 80 mg oral phytoestrogen (Promensil)/day insulin sensitivity was indirectly measured using the
quantitative insulin sensitivity check index (QUICKI). SHBG, total testosterone, oestradiol, and fasting glucose and insulin levels for calculation of
insulin sensitivity were obtained at baseline and at monthly intervals during the 3 months of therapy.
Results: In healthy nondiabetic postmenopausal women, the rate of change in QUICKI was signiﬁcantly different between the red clover based
phytoestrogen and transdermal oestrogen groups, so that after three months of therapy, QUICKI with red clover based phytoestrogen therapy
was lower than that in the transdermal oestrogen group, p = 0.01. Red clover based phytoestrogen therapy was not associated with any
changes in SHBG levels whereas transdermal estrogen therapy signiﬁcantly increased SHBG levels, p = 0.05.
Conclusions: In contrast to transdermal oestrogen therapy, oral phytoestrogen therapy does not decrease androgenicity and is associated
with a decrease in insulin sensitivity. These effects are similar to those of raloxifene and consistent with phytoestrogen’s selective oestrogen
receptor modulator properties.
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Introduction
Although evidence supports that oestrogen therapy improves
insulin sensitivity, ameliorates arterial compliance and
promotes a more favorable lipid profile in women, current
evidence concerning the adverse consequences of hormonal
replacement in postmenopausal women has renewed interest
in alternatives to oestrogen therapy. These alternatives include
herbal products containing compounds with oestrogenic
properties derived from plants or phytoestrogens. One of
the most widely distributed phytoestrogens currently sold is
a red clover botanical supplement [1]. Much of the positive
data regarding the effects of phytoestrogens on menopausal
symptoms, cardiac risk factors and cancer prevention are
derived from observational studies. Prospective studies to
date suggest that red clover based phytoestrogens may have
similar effects to oestrogen therapy to improve metabolic risk
factors such as vascular endothelial function in postmenopausal
women with type 2 diabetes, arterial compliance in healthy
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postmenopausal women and possibly the lipid profile. Previous
prospective studies on the effects of red clover based
phytoestrogens on insulin resistance, however, have not
had consistent results and are more difficult to interpret
because insulin resistance was not the primary outcome. These
limited studies on insulin resistance were also performed in
different study populations, postmenopausal women with type
2 diabetes [2] or premenopausal women [3], therefore difficult
to compare.
The objective of this randomized study was to directly
compare the effects of a red clover based oral phytoestrogen
with transdermal oestrogen on insulin sensitivity in nondiabetic
postmenopausal women. Secondarily, we wanted to assess the
effects of these drugs on postmenopausal hormone levels and
levels of sex hormone-binding globulin (SHBG).
Methods
Subjects
Forty-three healthy postmenopausal women who were not
on hormone replacement therapy were enrolled. Subjects
were recruited through the Human Subjects Core of the
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University of Michigan Geriatrics Center and newspaper
advertisement. Subjects were screened before study entry with
a medical history, physical examination and laboratory tests,
which included a complete blood count, thyroid-stimulating
hormone and routine chemistries. Subjects were excluded
from participation if they had any history of deep venous
thrombosis, pulmonary embolism, uterine cancer, breast
cancer; or had contraindications to oestrogen; or had evidence
from the history, physical examination, or laboratory testing
of other significant underlying medical or psychiatric illness.
No subjects had a fasting glucose level that would indicate
a diagnosis of diabetes and no subjects reported polycystic
ovarian disease in their medical history. Each subject gave
written informed consent that was approved by the University
of Michigan Institutional Review Board.
Study Protocol
Subjects who fulfilled eligibility criteria were randomized to
one of four groups: (i) 0.05 mg transdermal oestrogen/day,
(ii) 0.1 mg transdermal oestrogen/day, (iii) 40 mg oral phytoe-
strogen (Promensil)/day or (iv) 80 mg oral phytoestrogen/day.
These doses of transdermal oestrogen were chosen because
they are the standard doses used in clinical practice for hor-
mone therapy in postmenopausal women. The doses of oral
phytoestrogen were chosen based on the results of a previ-
ous meta-analysis demonstrating that a dose of 47 mg/day of
soy isoflavone had clinically significant effects on metabolic
parameters related to cardiovascular health [4].
A 12-week study was proposed for two reasons. First, a
decrease in serum lipids and improvement of insulin sensitivity
has been shown after 12 weeks of therapy with transdermal
oestrogen [5] and oral soy isoflavone [4]. Secondly, because
combination therapy with oestrogen and progesterone would
be complicated by the known confounding of progesterone
to decrease insulin sensitivity [6], the exposure to unopposed
oestrogen was limited.
All subjects underwent fasting glucose and insulin measure-
ments at baseline and at monthly intervals for 3 months during
drug therapy, as well as hormone measurements for SHBG,
oestradiol, estrone, total and free testosterone.
Measurement of Insulin Sensitivity
Blood samples for glucose and insulin were collected in glass
tubes containing sodium heparin, stored on ice and separated
immediately after collection. Plasma was stored at −70◦C until
assay. Plasma glucose was measured using the autoanalyser
glucose oxidase method and plasma insulin by RIA in the
Core Laboratory of the Michigan Diabetes Research and
Training Center. Insulin sensitivity was determined using
the quantitative insulin sensitivity check index (QUICKI)
calculated by the equation: 1/{log[fasting insulin (μU/ml)]
+ log[fasting glucose (mg/dl)]} [7].
Measurement of Androgenicity
Plasma testosterone and oestradiol were measured using
chemiluminescence in the Core Laboratory of the University
of Michigan General Clinical Research Center. Plasma
SHBG levels were measured using a solid-phase, two-
site chemiluminescent enzyme immunometric assay for use
with the Immulite Automated Analyzer (Immulite SHBG,
Diagnostic Product Corp., Los Angeles, CA, USA). Plasma
samples were stored at −70◦C until assayed. All samples were
analysed in the same assay. The sensitivity of the SHBG assay
was 0.2 nmol/l. The intra-assay and interassay coefficients of
variation were 6.5 and 8.7%, respectively.
Data and Statistical Analysis
All subjects were analysed on an intent-to-treat basis.
Demographic and baseline characteristics were summarized
using descriptive statistics (N, mean and standard error)
and compared among the four subject groups using analysis
of variance (ANOVA). Body mass index (BMI, kg/m2) was
determined by dividing subjects’ weight in kilograms by their
height in metres squared. Percentage change of SHBG from
baseline was calculated at each follow-up for each of the four
subject groups, and the mean bars (with standard error) for low
transdermal oestrogen versus high dose and for low dose oral
phytoestrogen versus high dose are shown in figure 2. Values are
presented as mean ± standard error of the mean, except for the
subject characteristics and body composition measurements,
which are presented as mean ± standard deviation.
Mixed-effects regression models were used to compare the
effects of drug therapy on the following variables of interest:
SHBG, oestradiol, testosterone, glucose, insulin and insulin
sensitivity as measured by QUICKI. Covariates included in
these models were age, BMI, drug, time and drug-by-time.
The mixed-effect regression models properly accounted for
correlations among repeated measures, and also allowed for
heterogeneous variances. Data were analysed using SAS version
9.2 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism
version 4.03 for Windows (GraphPad Software, San Diego,
CA, USA).
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Figure 1. Change in insulin sensitivity as measured by quantitative insulin
sensitivity check index (QUICKI) over 3 months of drug therapy with either
transdermal oestradiol or oral phytoestrogen.
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Results
The mean age of the women studied was 68 years with a range
between 60 and 83 years, and they were somewhat overweight
as reflected by their mean BMI of 27 kg/m2. There were no
statistically significant differences with respect to age, BMI, or
hormone status at baseline between the four subject groups
(Table 1). In addition, there were no statistically significant
differences with respect to fasting glucose, fasting insulin or
QUICKI between the four subject groups at baseline (Table 1).
As shown in figure 1, the rate of change in QUICKI
was significantly different between the red clover based
phytoestrogen and transdermal estrogen groups, so that
after 3 months of drug therapy, QUICKI with red clover
based phytoestrogen therapy was lower than that in the
transdermal estrogen group (adjusted p = 0.01). We found
that age and BMI were significantly associated with SHBG
levels (age p = 0.03, BMI p = 0.001), and BMI was significantly
associated with QUICKI (p < 0.0001) (Table 2). Also shown in
Table 2, positive rates of change in QUICKI (increased insulin
sensitivity) were found for both doses of transdermal oestrogen,
whereas negative rates of change in QUICKI (decreased insulin
sensitivity) were found for both doses of oral phytoestrogens.
There was no statistically significant dose effect of either
therapy.
After 3 months of drug therapy, fasting glucose levels were
significantly higher in the oral phytoestrogen groups compared
with the transdermal oestrogen groups (unadjusted drug effect,
p = 0.01). However, after adjustment for age and BMI, the
effects of transdermal oestrogen and oral phytoestrogen therapy
on fasting glucose and insulin levels were no longer significant.
As expected, the transdermal oestrogen groups significantly
increased SHBG levels (Table 2, figure 2, adjusted p = 0.05).
Neither dose of oral phytoestrogen therapy changed SHBG
levels or oestradiol levels. There was no significant change in
total testosterone levels with either transdermal oestrogen or
oral phytoestrogen.
Discussion
The present study showed that in contrast to transdermal
oestrogen’s effect to maintain insulin sensitivity, red clover
based phytoestrogen therapy was associated with a significant
decrease in insulin sensitivity in healthy nondiabetic post-
menopausal women. We did not find any dose effect; therefore,
the high and low doses of each therapy were combined for
some of the analyses.
Postmenopausal oestrogen therapy is generally believed to
improve insulin sensitivity and may decrease the risk for type 2
diabetes. Because red clover based phytoestrogen therapy shares
some other positive effects of oestrogen therapy, we postulated
that it would also improve insulin sensitivity. Soy protein,
as well as genistein specifically, has been shown to decrease
insulin resistance in postmenopausal women with and without
type 2 diabetes [8,9]. Different red clover based phytoestrogens
have been shown to have no effect on indirect measures
of insulin sensitivity in postmenopausal women with type 2
diabetes and premenopausal women. No previous studies have
directly examined the effect of red clover based phytoestrogens
on insulin sensitivity in healthy postmenopausal women. In
contrast to the results of the few limited prior studies on red
clover based phytoestrogens, in the present study red clover
based phytoestrogen therapy was shown to significantly reduce
insulin sensitivity.
The effects of red clover based phytoestrogens on insulin
sensitivity observed in our present study are similar to those pre-
viously reported for raloxifene [10], and therefore consistent
with phytoestrogen’s selective oestrogen receptor modulator
(SERM) properties. Phytoestrogens have a similar molecular
structure to other SERMs and to oestrogen, are known to
bind to oestrogen receptors and compete with the oestradiol
receptor complex for nuclear binding. This appears to account
for the ability of phytoestrogens to act as either an oestro-
gen agonist or antagonist [11]. Phytoestrogens may also differ
from oestradiol by being more potent oestrogen receptor beta
agonists rather than oestrogen receptor alpha agonists [12]. In
addition to the differential activity of phytoestrogens at the
oestrogen receptor and competition with oestradiol at the cel-
lular level, phytoestrogen absorption from the intestinal tract
may stimulate production of SHBG thus lowering free oestra-
diol levels in the circulation. However, we did not see any effect
of red clover based phytoestrogens on SHBG, oestradiol or
testosterone levels in this study. Another potential mechanism
for the differential activity of phytoestrogens may be because of
alteration of aromatase activity leading to a decrease in active
oestrogen concentrations. This may be because of structural
Table 1. Baseline subject characteristics.∗
Transdermal oestrogen
(0.5 mg), N = 10
Transdermal oestrogen
(1.0 mg), N = 11
Oral isoflavone
(40 mg), N = 10
Oral isoflavone
(80 mg), N = 12
Age (years) 72 ± 8 65 ± 5 69 ± 7 67 ± 6
BMI (kg/m2) 26 ± 5 29 ± 6 26 ± 4 26 ± 5
SHBG (nM) 83.7 ± 30 55.0 ± 26 85.5 ± 45 56.2 ± 24
Total testosterone (nM) 0.016 ± 0.01 0.013 ± 0.01 0.005 ± 0.0008 0.005 ± 0.001
Oestradiol (pM) 135.5 ± 79.0 62.4 ± 8.7 44.8 ± 5.4 61.5 ± 4.4
Glucose (mM) 5.3 ± 0.2 5.2 ± 0.2 5.1 ± 0.2 5.5 ± 0.2
Insulin (pM) 85.84 ± 12.0 84.0 ± 8.7 100.8 ± 22.5 98.9 ± 18.4
QUICKI 0.331 ± 0.006 0.332 ± 0.006 0.330 ± 0.009 0.326 ± 0.007
BMI, body mass index; SHBG, sex hormone-binding globulin; QUICKI, quantitative insulin sensitivity check index.
∗Group comparisons were carried out using ANOVA. No statistically significant differences among the four subject groups were found for all variables.
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Table 2. Results from mixed-effects models.
Outcome
SHBG QUICKI
Parameter Estimate (SE) p Estimate (SE) p
Age 1.51 (0.69) 0.03 −0.12E-3 (0.4E-3) 0.7876
BMI −2.86 (0.86) 0.0013 −2.57E-3 (0.5E-3) <0.0001
Drug (baseline) 0.16 0.51
Transdermal oestrogen (0.5 mg) 75.2 (10.5) 0.33 (0.006)
Transdermal oestrogen (1.0 mg) 68.6 (9.96) 0.34 (0.006)
Oral phytoestrogen (40 mg) 79.8 (9.47) 0.33 (0.007)
Oral phytoestrogen (80 mg) 52.9 (8.38) 0.32 (0.005)
Slope 0.06 0.08
Transdermal oestrogen (0.5 mg) 3.50 (2.99) 0.51E-3 (0.001)
Transdermal oestrogen (1.0 mg) 7.22 (3.10) 0.21E-3 (0.001)
Oral phytoestrogen (40 mg) −2.41 (2.45) −5.08E-3 (0.002)
Oral phytoestrogen (80 mg) 2.67 (2.09) −2.64E-3 (0.001)
Difference in slopes
Transdermal oestrogen: HI—LO 3.73 (4.31) 0.39 −0.29E-3 (0.002) 0.87
Oral phytoestrogen: HI—LO 5.08 (3.22) 0.12 2.43E-3 (0.003) 0.38
Oestrogen—oral isoflavone 5.23 (2.69) 0.05 4.22E-3 (0.002) 0.01
BMI, body mass index; SHBG, sex hormone-binding globulin; QUICKI, quantitative insulin sensitivity check index.
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Figure 2. Percentage of change in sex hormone-binding globulin (SHBG) levels over 3 months of drug therapy with either transdermal oestradiol or oral
phytoestrogen.
features of the isoflavones found in red clover which increases
their binding affinity to aromatase thus inhibiting aromatase
activity [13]. One of the isoflavones isolated from red clover,
biochanin A, has been shown to have aromatase inhibitor activ-
ity at the transcriptional level [14]. Therefore, phytoestrogens
may act as oestrogen antagonists through various mechanisms
and therefore have an opposite effect on insulin sensitivity
compared to oestrogen therapy.
One of the potential limitations of this study is that the
effects of the currently studied red clover based phytoestrogen
(Promensil), on insulin sensitivity, may be different from
the effects of soy based oral phytoestrogens. For this study,
a red clover based phytoestrogen was chosen because it is
one of the most widely distributed phytoestrogens currently
sold as an alternative to hormone replacement therapy
for postmenopausal women. Red clover phytoestrogens are
composed of the isoflavones present in soy, genistein and
daidzein, as well as the soy isoflavone precursors, biochanin
A and formomonectin. One small randomized, placebo-
controlled study showed that the absorption of isoflavones
from soy was similar to that of red clover [15].
In summary, after 12 weeks of drug therapy, oral phytoe-
strogen decreased insulin sensitivity in healthy nondiabetic
postmenopausal women. Although red clover phytoestrogens
may have a total isoflavone content similar to soy based phy-
toestrogens, this may not necessarily apply to other forms of
phytoestrogens. The clinical significance of this finding high-
lights possible adverse side effects of alternatives to oestrogen
therapy that warrant further evaluation in future studies.
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